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Recently Christian Hudert and colleagues from the Charité in Berlin published a study about genetic determinants in pediatric non-alcoholic liver disease (Hudert et al., 2018\[[@R9]\]). Non-alcoholic fatty liver disease (NAFLD), the most frequent chronic liver disease in children, is known to be strongly influenced by genetic factors (Nobili et al., 2016\[[@R14]\]; Schwimmer et al., 2006\[[@R17]\]; Makkonen et al., 2009\[[@R12]\]; Anstee et al., 2016\[[@R2]\]). However, genetic determinants of a portal/zone-1 pattern of steatosis in children are not yet known. This would be important, because a portal/zone-1 pattern of steatosis leads to an increased risk of disease progression to fibrosis (Africa et al., 2018\[[@R1]\]; Mann et al., 2016\[[@R13]\]). To address this question, the authors established the Berlin adolescence NAFLD cohort (BaNA) and studied a set of single nucleotide polymorphisms. Interestingly, a variant of the retinyl-palmitate lipase PNPLA3 (rs738409) was associated with a periportal pattern of steatosis and also with an increased risk of progression to fibrosis (Hudert et al., 2018\[[@R9]\]). Therefore, obese children with the PNPLA3 variant may be candidates for a more intensive clinical follow-up and intervention.

Due to the current increase in the incidence of liver diseases a better understanding of their pathophysiology is of major importance (Jansen et al., 2017\[[@R11]\]; Vartak et al., 2016\[[@R20]\]; Hammad et al., 2014\[[@R7]\]; Hassan, 2016\[[@R8]\]; Stöber, 2016\[[@R18]\]; Bolt, 2017\[[@R3]\]; Ekhlasi et al., 2017\[[@R5]\]). For this purpose systems modeling as well as the analysis of expression patterns in relation to a phenotype represent frequently applied tools (Godoy et al., 2016\[[@R6]\]; Crespo Yanguas et al., 2016\[[@R4]\]; Jain et al., 2016\[[@R10]\]; Saleem et al., 2016\[[@R15]\]; Schenk et al., 2017\[[@R16]\]; Thiel et al., 2015\[[@R19]\]). The newly established BaNA cohort of adolescent NAFLD with its careful phenotyping and availability of proteome data is an important milestone for a better understanding of disease progression in steatosis.
